OPIANT PHARMACEUTICALS, INC.: 10-Q filed 2016-12-15
What OPIANT PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-12-15 (fiscal Q1 2017): 22 published measures, 46 facts as tagged in accession 0001144204-16-139775.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-12-15
- Fiscal period
- fiscal Q1 2017
- Accession
- 0001144204-16-139775 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 1,977,886 | USD | |
| At 2016-07-31 | 1,881,878 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 7,102,503 | USD | |
| At 2016-07-31 | 6,586,834 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | -5,124,617 | USD | |
| At 2016-07-31 | -4,704,956 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 1,184,568 | USD | |
| At 2016-07-31 | 1,481,393 | USD | |
| At 2015-10-31 | 455,249 | USD | |
| At 2015-07-31 | 434,217 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | -600,628 | USD | 92 |
| 2015-08-01 to 2015-10-31 | -11,110,017 | USD | 92 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | 1,121,142 | USD | 92 |
| 2015-08-01 to 2015-10-31 | 120,000 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | -61,785,970 | USD | |
| At 2016-07-31 | -61,185,342 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | 0 | USD | 92 |
| 2015-08-01 to 2015-10-31 | 0 | USD | 92 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 5,579 | USD | |
| At 2016-07-31 | 6,521 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | -579,030 | USD | 92 |
| 2015-08-01 to 2015-10-31 | -11,100,830 | USD | 92 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 1,953,588 | USD | |
| At 2016-07-31 | 1,856,295 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 4,752,503 | USD | |
| At 2016-07-31 | 4,236,834 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 699,142 | USD | |
| At 2016-07-31 | 312,498 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | 1,700,172 | USD | 92 |
| 2015-08-01 to 2015-10-31 | 11,220,830 | USD | 92 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | 441,834 | USD | 92 |
| 2015-08-01 to 2015-10-31 | 429,450 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 1,992,433 | shares | |
| At 2016-07-31 | 1,992,433 | shares |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 1,958 | USD | |
| At 2016-07-31 | 1,016 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-10-31 | 18,719 | USD | |
| At 2016-07-31 | 19,062 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | 1,216,302 | USD | 92 |
| 2015-08-01 to 2015-10-31 | 10,791,380 | USD | 92 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | -21,598 | USD | 92 |
| 2015-08-01 to 2015-10-31 | -9,187 | USD | 92 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | 386,644 | USD | 92 |
| 2015-08-01 to 2015-10-31 | 0 | USD | 92 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-08-01 to 2016-10-31 | 500,870 | USD | 92 |
| 2015-08-01 to 2015-10-31 | -208,358 | USD | 92 |
Inspect the source
- Entity
- OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
- Captured
- SEC response SHA-256
2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))